A3: Efficacy and Safety of Adalimumab in Pediatric Patients With Enthesitis Related Arthritis
Bibliographic record
Abstract
Background/Purpose: Enthesitis related arthritis (ERA) is a subcategory of juvenile idiopathic arthritis (JIA) which primarily affects peripheral joints and entheses but also can involve the sacroiliac joints and spine. It causes long‐term effects on both physical and quality aspects of a child's life (). Adalimumab (ADA) has been previously demonstrated to be effective in polyarticular JIA. The purpose of this study was to evaluate the efficacy and safety of adalimumab compared to placebo in children and adolescents with ERA. Methods: This is a phase 3, multicenter, randomized, double‐blind (DB) study in patients (pts) aged ≥6 to <18 years (yr) with ERA (ILAR criteria) with active disease not responsive to ≥1 nonsteroidal antiinflammatory drug and ≥1 disease‐modifying antirheumatic drug. Active disease was defined as ≥3 active joints (swelling or loss of motion + pain/tenderness) and enthesitis in ≥1 location (past or present). Pts were randomized 2:1 to receive blinded ADA (24 mg/m2 BSA up to 40 mg every other week (wk) [eow]) or placebo (PBO) for 12 wks followed by open‐label (OL) ADA eow up to 144 wks. The primary endpoint was % change from baseline (BL) in the number of active joints with arthritis (AJC) at wk 12. Secondary variables assessed included enthesitis count (EC), tender and swollen joint counts, and American College of Rheumatology (ACR) Pediatric (Pedi) 30/50/70 responses. Results are summarized through 52 wks of treatment. Safety was assessed in terms of adverse events (AE), laboratory values, and vital sign measurements. Results: 46 pts were randomized (31 to ADA, 15 to PBO). No pts discontinued during the DB period; however, 7 pts early escaped to OL ADA. Mean age was 12.9±2.9 yrs. At BL, mean duration of ERA symptoms was 2.6±2.3 yrs; mean AJC was 7.8±6.6, and mean EC was 8.1±8.4. The % change from BL at wk 12 in AJC was greater in the ADA group vs. PBO (−62.6±59.5 vs −11.6±100.5, P=0.039). Most secondary variables showed numerically greater, but not statistically significant improvement at wk 12 in favor of ADA vs. PBO (). Treatment response was maintained with continued ADA therapy up to 52 wks (% change from BL at wk 52 in AJC, −88.7±26.1). During the DB period AE incidence rates were similar [ADA/PBO (%)]: any AE (67.7/53.3), serious AE (3.2/0, 1 pt in the ADA group [abdominal pain and headache]), and infectious AEs (29.0/20.0). Among pts who received at least 1 dose of ADA through wk 52, any AE, serious AEs, and infectious AEs were reported in 91.3%, 10.9%, and 76.1%, respectively. No deaths, TB, or malignancies were reported. At Week 12 ADA (N=31) PBO (N=15) Change from Baseline a (mean ± SD) # enthesitis sites (0–35) −4.4 ± 6.2 −2.7 ± 5.0 Tender joint count (0–72) −7.9 ± 8.3 −4.5 ± 9.0 Swollen joint count (0–68) −3.5 ± 5.6 −2.4 ± 4.7 ACR Pedi Response b (n, %) ACR Pedi30 responder 21 (67.7) 10 (66.7) ACR Pedi50 responder 20 (64.5) 7 (46.7) ACR Pedi70 responder 16 (51.6) 4 (26.7) Conclusion: ADA reduced the signs and symptoms of ERA at wk 12 and efficacy was sustained up to 52 wks. The safety profile observed in pediatric patients with ERA was consistent with that observed in children aged ≥2 years treated for polyarticular JIA.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".